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Abstract 
Background: Indoleamine 2,3-dioxygenase catalyzes the conversion of tryptophan to kynurenine, an immunosup-
pressive metabolite involved in T regulatory cell differentiation. Indoleamine 2,3-dioxygenase is expressed in many 
cancer types, including breast cancer. Here, we analyze kynurenine and tryptophan and their ratio in breast cancer 
patients and healthy controls.
Methods: Breast cancer patients and healthy controls were prospectively enrolled in our study. All subjects under-
went blood sample withdrawal at diagnosis or on the day of screening mammography for the healthy controls. Plas-
matic kynurenine and tryptophan were determined on a TQ5500 tandem mass spectrometer after chromatographic 
separation.
Results: We enrolled 146 healthy controls and 202 women with stages I–III breast cancer of all subtypes. All patients 
underwent surgery, 126 underwent neoadjuvant chemotherapy with 43 showing a pathological complete response, 
and 43 underwent adjuvant chemotherapy. We observed significantly higher plasmatic kynurenine, tryptophan and 
their ratio for the healthy controls compared to patients with breast cancer. We observed a lower plasmatic tryp-
tophan and a higher kynurenine/tryptophan ratio in hormone receptor-negative patients compared to hormone 
receptor-positive cancers. Lobular cancers showed a lower ratio than any other histologies. Advanced cancers were 
associated with a lower tryptophan level and higher grades with an increased kynurenine/tryptophan ratio. Patho-
logical complete response was associated with higher kynurenine values. The plasmatic kynurenine, tryptophan and 
kynurenine/tryptophan ratios were not predictive of survival.
Conclusions: The plasmatic kynurenine, tryptophan and kynurenine/tryptophan ratio could differentiate breast 
cancer patients from healthy controls. The Kyn/Trp ratio and Trp also showed different values according to hormone 
receptor status, TNM stage, T grade and histology. These results suggest a rapid metabolism in breast cancer, but no 
associations with outcome or sensitivity to chemotherapy were observed.
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Background
Tryptophan (Trp) catabolism is a known mechanism 
involved in immune system modulation and is widely 
studied in cancer. Trp is metabolized by indoleamine 
2,3-dioxygenase (IDO), by its splice variant IDO2 and 
by tryptophan 2,3-dioxygenase (TDO) [1]. IDO2 expres-
sion is narrower than IDO, and it is inactivated in a large 
percentage of the population due to some common poly-
morphisms, namely, R248W, that reduces IDO activity 
in approximately 90% of individuals, and Y359, which 
completely abolishes its catalytic function [2]. TDO is 
expressed at high levels in the liver, where it regulates 
systemic Trp levels, and in the brain, where it is respon-
sible for the production of neuroactive metabolites, such 
as kinurenic and quinolinic acid [3]. IDO seems to play 
a central role in maintaining immune tolerance. Previ-
ous studies showed that IDO-deficient mouse models are 
more susceptible to autoimmune disease, while TDO-
deficient mice showed only behavioral alterations [3, 4]. 
IDO expression is induced in response to some inflam-
matory cytokines, such as interferon-γ (IFN-γ), acting as 
an endogenous mechanism able to control an excessive 
immune response [5]. IDO is expressed by several tumor 
types and is correlated with lower cytotoxic cells and 
higher T regulatory (Treg) cell infiltration at the tumor 
site, poorer outcome and resistance to treatment [6–16].
Trp depletion induces an arrest at the G1 phase of 
the cell cycle, blocking T-lymphocyte proliferation, and 
triggers a stress response mediated by the activation of 
the nonderepressible kinase GCN2 pathway, which is 
responsible for T-cell anergy and apoptosis [17]. When 
exposed to low Trp levels, dendritic cells (DC) acquire 
tolerogenic capacity. DC showed an upregulation of the 
immunoglobulin-like transcript 3 and 4 inhibitory recep-
tors (ILT3 and ILT4) and a lower expression of costimula-
tory molecules, such as CD40 and CD80 [18]. The high 
expression of ILT3 and ILT4 leads to the differentiation 
of CD4+CD25+Foxp3+ Treg cells [18]. Moreover, Trp 
catabolites, i.e. kynurenine (Kyn) and its downstream 
metabolites, acting through the activation of the aryl 
hydrocarbon receptor (AHR), are also responsible for 
Treg differentiation and in inhibition of T lymphocytes 
and natural killer (NK) cells [19, 20].
IDO is expressed in several tumor types, including 
breast cancer. A retrospective analysis conducted on 203 
breast cancer patients showed that none of the tumor 
samples were negative for IDO staining in immuno-
histochemistry [21]. Larger, node-positive and estro-
gen receptor-positive (ER+) tumors were associated 
with higher IDO expression, while greater vascular-
ized tumors showed lower IDO staining [21]. A greater 
CD8+ and CD11b+ cell infiltration was observed in low-
IDO tumors, while Treg infiltration was not associated 
with IDO expression in this report [21]. Another study 
reported a negative association between high stromal 
IDO and worse disease-free and metastasis-free survival 
in breast cancer [22].
The plasmatic Kyn/Trp ratio is commonly used as a 
surrogate indicator of IDO activity, even though it might 
be an imperfect reflection of the tumor Trp catabolism. 
Lyon and colleagues observed a higher plasmatic Kyn/
Trp ratio in patients affected by breast cancer compared 
to healthy controls, but not a statistically significant dif-
ference in the plasmatic level of the two molecules [23]. 
Another more recent study showed significantly lower 
plasmatic Trp and Kyn levels in breast cancer patients 
than in healthy controls, mainly in estrogen receptor-
negative (ER−) tumors and at an advanced tumor stage 
[24]. Tang and colleagues observed higher Kyn plasmatic 
levels in ER− compared to ER+ cancers [25]. Overall, the 
previously mentioned studies did not unequivocally iden-
tify an association between tumor characteristics and the 
plasmatic Kyn, Trp and Kyn/Trp ratio, in addition to not 
showing an association with outcome, despite what was 
observed in other diseases [14–16].
In the present study, we analyzed the plasmatic levels 
of Trp, Kyn and their ratio in a large cohort of stage I–
III breast cancer patients undergoing surgery ± neoadju-
vant/adjuvant treatment and in healthy controls. The aim 
of our study was to identify differences in Kyn, Trp and 
the Kyn/Trp ratios in plasma between healthy and can-
cerous women to analyze the association of these param-
eters with outcome, their distribution according to tumor 




This was an observational prospective study in which 
stage I–III breast cancer patients treated with surgery 
with or without adjuvant/neoadjuvant treatment, radio-
therapy and hormonal therapy according to clinical 
practice at the University Hospital of Liège in Belgium 
between May 2011 and August 2017 were enrolled.
Healthy controls were enrolled between January and 
November 2014 at the University Hospital of Liège in 
Belgium before performing a screening mammography 
and were allocated to the control group after confirma-
tion of the absence of breast disease.
For all breast cancer patients, the following data were 
collected: ER status, progesterone receptor (PgR) status, 
HER2 status, Ki67, TNM stage, tumor size, tumor grade, 
type of treatment, response to chemotherapy for patients 
who received neoadjuvant chemotherapy (NAC), dis-
ease-free survival (DFS) and breast cancer-specific sur-
vival (BCSS).
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This study was conducted in accordance with the Dec-
laration of Helsinki. The institutional ethics committee 
approved the protocols, and each patient or healthy con-
trol signed informed consent before inclusion in the trial.
Sample collection and storage
Blood sample withdrawal into an EDTA tube was per-
formed before receiving any treatment for breast cancer 
patients or before the day of the screening mammogra-
phy for healthy controls. After two centrifugation steps 
for 10 min at 815g and for 10 min at 2500g at 4 °C, plasma 
was collected in aliquots and stored at − 80  °C without 
thawing cycles until the sample analysis.
Tryptophan and kynurenine determination
The plasmatic samples were used to determine the Kyn 
and Trp concentrations. After the step of protein precipi-
tation with salicylic acid, the Kyn and Trp concentrations 
were determined on a TQ5500 tandem mass spectrom-
eter after chromatographic separation. The values were 
calculated by the software Analyst, comparing the spec-
trometer intensity with known concentrations of internal 
standards for Trp and Kyn. The final concentrations were 
expressed in μM/L. Each sample was tested in triplicate, 
and the mean value was used for the statistical analysis.
Statistical analysis
Statistical analyses and graphs were performed using 
IBM SPSS Statistic v24, MedCalc v19 and Prism v5 
GraphPad software.
The co-primary end-points of our study were to assess 
the different distributions of plasmatic Kyn, Trp and the 
Kyn/Trp ratio in breast cancer (BC) patients compared to 
healthy controls (CTRL).
The secondary end-points were to identify the differ-
ent distribution of plasmatic Kyn, Trp and the Kyn/Trp 
ratio according to patient and tumor characteristics (age, 
ER status, PgR status, HER2 status, Ki67, TNM stage, 
T stage, N stage, tumor grade, histology, subtype, lym-
phovascular invasion, response to NAC and relapse in 
the whole cohort and according to the different BC sub-
types), to test the correlation between plasmatic Kyn, Trp 
and the Kyn/Trp ratio with the continuous variables age, 
ER, PgR, Ki67 and size and to assess DFS and BCSS in 
patients with Kyn, Trp and the Kyn/Trp ratio low vs. high.
The Mann–Whitney U test and Kruskal–Wallis test 
were used to compare the distributions of circulating 
Kyn, Trp and their ratio according to the following vari-
ables: cancer patients vs. healthy controls; age at diagno-
sis higher or lower than the median value; ER status; PgR 
status; HER2 status; Ki67; TNM stage; T stage; N stage; 
tumor grade; histology; subtype; lymphovascular inva-
sion; response to neoadjuvant chemotherapy (NAC) and 
relapse. A post hoc Bonferroni test was performed for 
comparison by pairs for variables with multiple catego-
ries. An alpha level of 0.05 was accepted for significant 
results.
Spearman test was performed to analyze the correla-
tion between plasma Kyn and Trp and their ratio with 
the following continuous variables: age, ER%, PgR%, 
Ki67% and tumor size in mm. An alpha level of 0.05 was 
accepted for significant results.
The median values of circulating Kyn, Trp and the Kyn/
Trp ratio for cancer patients were calculated and used 
as cut-offs to classify patients into two groups for each 
variable. Kaplan–Meier curves for DFS and BCSS were 
drafted, and the statistical significance was tested by 
means of a log-rank test, with an accepted alpha level of 
0.05. The 5-year DFS and the 5-year BCSS were calcu-
lated from the survival tables. The Cox Regression Haz-
ard model was used to calculate the HR for both DFS and 
BCSS.
Results
In total, 348 subjects, 146 of whom were healthy controls 
(CTRL) and 202 of whom were stage I–III breast cancer 
(BC) patients, were enrolled in this study between May 
2011 and August 2017 at the University Hospital of Liège 
in Belgium.
The median age for the whole cohort was 54.5  years 
(range 26–86). In particular, the median age in the group 
of 202 breast cancer patients was 56  years old (range 
26–86), while the median age in the healthy controls 
group was 53  years old (range 40–74). The median fol-
low-up was 60 months (range 14–96). The patients were 
classified as stage I in 20.8%, stage II in 55% and stage III 
in 24.3% of the cases. All the breast cancer subtypes were 
included in the study: Luminal A in 29.7%; Luminal B in 
44.1%; HER2-enriched in 6.9% and triple-negative breast 
cancer (TNBC) in 19.3% of the cases. All patients under-
went surgery and received neoadjuvant/adjuvant chemo-
therapy, trastuzumab, radiotherapy and hormonotherapy 
according to cancer characteristics and physician choice. 
All patient characteristics and treatment details are sum-
marized in Table 1.
Circulating Kyn was significantly lower in the BC 
patients than in the healthy CTRLs, with a median value 
of 1.770 ± 0.537 μM/L vs. 1.951 ± 0.708 μM/L (p < 0.0001), 
respectively. The same observation was found for the 
Trp value in plasma, which was 44.56 ± 10.83 μM/L and 
48.80 ± 14.16  μM/L in the BCs and CTRLs respectively 
(p 0.001), and for the plasmatic Kyn/Trp ratio, which was 
0.038 ± 0.013 for the BC patients and 0.042 ± 0.019 for 
the healthy CTRLs (p 0.026) (Table 2 and Fig. 1). 
The Kyn and Kyn/Trp ratio in plasma showed a dif-
ferent distribution according to age in the entire 
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cohort, with a lower plasmatic concentration of Kyn 
(1.738 ± 0.609 μM/L vs. 1.980 ± 0.643 μM/L, p < 0.0001) 
and Kyn/Trp ratio (0.036 ± 0.015 vs. 0.043 ± 0.016, 
p < 0.0001) for patients younger than 54.5  years 
(Table 2). Consistently, we observed a significant posi-
tive correlation between the age and circulating Kyn 
or Kyn/Trp ratio, with correlation coefficients of 0.295 
(p < 0.0001) and 0.300 (p < 0.0001), respectively (Table 3 
and Additional file 1: Figure S3).




Median age: 56 years
Range: 26–86 years
Histology
 Ductal carcinoma 172 85.1
 Lobular carcinoma 23 35.4
 Other 7 3.5
Subtype
 Luminal A 60 29.7
 Luminal B 89 44.1
 HER2-enriched 14 6.9
 TNBC 39 19.3
ER status
 Positive 145 71.8
 Negative 57 28.2
PgR status
 Positive 131 64.9
 Negative 71 35.1
HER2 status
 Positive 55 27.2
 Negative 147 72.8
Ki67
 < 20% 74 36.6
 ≥ 20% 127 62.9
 Unk 1 0.5
Stage
 I 42 20.8
 II 111 55
 III 49 24.3
T stage
 1 64 31.7
 2 89 44
 3 21 10.4
 4 27 13.4
 Unk 1 0.5
N stage
 0 101 50
 1 82 40.6
 2 10 5
 3 6 3
 Unk 3 1.4
Tumor grade
 G1 5 2.5
 G2 100 49.5
 G3 91 45
 Unk 6 3
Lymphovascular invasion
 Yes 41 20.3
 No 156 77.2






 Yes 126 72.4
 No 76 37.6
Type of NAC (N = 126)
 EC → Taxane 94 74.6
 FEC → Taxane 21 16.7
 EC → CBDCA-Ptx 6 4.8
 Other 5 4
Pathological complete response (N = 126)
 Yes 43 34.1
 No 83 65.9
Adjuvant chemotherapy (AC)
 Yes 43 21.3
 No 159 78.7
Type of AC (N = 43)
 EC → Taxane 11 25.6
 FEC → Taxane 20 9.9
 Capecitabine 5 11.6
 Other 7 3.5
Trastuzumab
 Yes 53 26.2
 No 149 73.8
Radiotherapy
 Yes 174 86.1
 No 28 13.9
Hormonotherapy
 Yes 149 73.2
 No 54 26.8
Type of hormonotherapy
 SERM 56 37.6
 AI 79 53
 SERM + AI 14 9.4
Relapse
 Yes 28 13.9
 No 174 86.1
TNBC triple-negative breast cancer, Unk unknown, NAC neoadjuvant 
chemotherapy, AC adjuvant chemotherapy, EC epirubicin–cyclophosphamide, 
FEC 5-fluorouracil–epirubicin–cyclophosphamide, CBDCA carboplatin, Ptx 
paclitaxel, N number of patients, SERM selective estrogen receptor modulator, AI 
aromatase inhibitor
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Table 2 Kyn, Trp and Kyn/Trp ratio according to patient and tumor characteristics
Comparison group Kyn (μM/L) Trp (μM/L) Kyn/Trp ratio
Median ± SD P value Median ± SD P value Median ± SD P value
Healthy vs. cancer
 Healthy 1.951 ± 0.708 < 0.0001*** 48.80 ± 14.16 0.001** 0.042 ± 0.019 0.026*
 Cancer 1.770 ± 0.537 44.56 ± 10.83 0.038 ± 0.013
Age (years)
 < 54.5 1.738 ± 0.609 < 0.0001*** 45.68 ± 11.23 0.978 0.036 ± 0.015 < 0.0001***
 ≥ 54.5 1.980 ± 0.643 46.63 ± 13.78 0.043 ± 0.016
Histology
 Ductal 1.810 ± 0.550 0.077 44.51 ± 10.65 0.051 0.038 ± 0.014 0.005**
 Lobular 1.550 ± 0.451 48.60 ± 11.54 0.033 ± 0.009
 Other 1.543 ± 0.289 38.00 ± 10.92 0.038 ± 0.008
Subtype
 Luminal A 1.770 ± 0.570 0.324 47.73 ± 12.48 0.213 0.038 ± 0.014 0.100
 Luminal B 1.800 ± 0.458 44.57 ± 10.27 0.038 ± 0.011
 HER2-enriched 1.853 ± 0.881 40.42 ± 6.85 0.047 ± 0.023
 TNBC 1.707 ± 0.442 44.13 ± 9.90 0.038 ± 0.012
Estrogen receptor expression
 ER-positive 1.800 ± 0.510 0.897 45.47 ± 11.26 0.016* 0.0377 ± 0.012 0.040*
 ER-negative 1.757 ± 0.606 42.00 ± 8.88 0.042 ± 0.016
Progesterone receptor expression
 PgR-positive 1.775 ± 0.480 0.890 44.93 ± 11.64 0.041* 0.038 ± 0.012 0.048*
 PgR-negative 1.760 ± 0.633 43.73 ± 8.59 0.041 ± 0.016
HER2 amplification
 HER2-positive 1.797 ± 0.643 0.364 43.66 ± 10.16 0.313 0.039 ± 0.017 0.100
 HER2-negative 1.766 ± 0.489 44.93 ± 11.09 0.038 ± 0.012
Ki67% expression
 Ki67 < 20% 1.757 ± 0.577 0.968 47.17 ± 1.02 0.240 0.038 ± 0.014 0.328
 Ki67 ≥ 20% 1.800 ± 0.518 43.93 ± 10.06 0.038 ± 0.013
TNM stage
 Stage I 1.652 ± 0.555 0.668 47.30 ± 12.75 0.035* 0.037 ± 0.011 0.143
 Stage II 1.807 ± 0.489 45.47 ± 10.18 0.038 ± 0.014
 Stage III 1.697 ± 0.631 40.60 ± 9.90 0.042 ± 0.015
T stage
 T1 1.800 ± 0.538 0.935 48.58 ± 12.36 0.024* 0.037 ± 0.011 0.352
 T2 1.757 ± 0.516 44.47 ± 8.28 0.038 ± 0.014
 T3 1.677 ± 0.642 40.60 ± 12.31 0.039 ± 0.016
 T4 1.807 ± 0.550 41.23 ± 11.45 0.043 ± 0.015
N stage
 N0 1.677 ± 0.515 0.736 44.67 ± 11.91 0.492 0.037 ± 0.013 0.538
 N1 1.813 ± 0.503 44.90 ± 9.95 0.039 ± 0.013
 N2 1.705 ± 0.641 44.20 ± 7.63 0.044 ± 0.012
 N3 1.651 ± 1.106 39.5 ± 8.60 0.044 ± 0.022
Scarf–Bloom–Richardson grade
 G1 1.520 ± 0.522 0.143 40.60 ± 8.33 0.843 0.034 ± 0.005 0.026*
 G2 1.670 ± 0.605 44.40 ± 11.61 0.036 ± 0.015
 G3 1.840 ± 0.450 44.57 ± 10.20 0.038 ± 0.011
Lymphovascular invasion
 Yes 1.820 ± 0.657 0.286 45.47 ± 8.73 0.694 0.039 ± 0.014 0.272
 No 1.728 ± 0.500 44.35 ± 11.33 0.038 ± 0.013
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In the cohort of cancerous patients, a statisti-
cally significant lower Trp level and higher Kyn/Trp 
ratio in plasma were observed for the ER− and PgR− 
patients compared to ER+ and PgR+ patients, respec-
tively (Table  2). In particular, the values of circulating 
Trp were 42.00 ± 8.88  μM/L vs. 45.47 ± 11.26  μM/L 
(p 0.016) in ER− vs. ER+ and 43.73 ± 8.59  μM/L vs. 
44.93 ± 11.64  μM/L (p 0.041) in PgR− and PgR+, 
respectively. The values of the plasmatic Kyn/Trp 
ratio were 0.042 ± 0.016 in ER− vs. 0.0377 ± 0.012 in 
ER+ patients (p 0.040) and 0.041 ± 0.016 in PgR− vs. 
0.038 ± 0.012 in PgR+ patients (p 0.048). The correla-
tion analysis showed a positive correlation between 
ER% and circulating Trp level and a negative correla-
tion between PgR% and the Kyn/Trp ratio in plasma, as 
reported in Table 3 and in Additional file 1: Figure S3.
A lower plasmatic Kyn/Trp ratio for lobular carcino-
mas compared to the other histologies was also detected, 
particularly with a ratio of 0.033 ± 0.009 for lobular, 
0.038 ± 0.014 for ductal and 0.038 ± 0.008 for other his-
tologies (p 0.005). A comparison by pairs confirmed the 
difference between ductal and lobular carcinoma with a p 
value of 0.011 (Additional file 1: Table S1).
Moreover, the plasmatic Kyn/Trp ratio showed pro-
gressively higher values with increasing tumor grade, 
particularly 0.034 ± 0.005 for G1, 0.036 ± 0.015 for G2 
and 0.038 ± 0.011 for G3 (p 0.026). The comparison by 
pairs did not confirm this difference (Additional file  1: 
Table  S6), probably due to the low number of patients 
classified as G1.
We also observed a progressively lower circulat-
ing Trp level according to the increase of T (from 
48.58 ± 12.36  μM/L in T1 to 41.23 ± 11.45  μM/L in T4, 
p 0.024) and TNM stage (from 47.30 ± 12.75  μM/L for 
Stage I to 40.60 ± 9.90  μM/L for Stage III, p 0.035). In 
particular, plasmatic Trp showed a significantly differ-
ent distribution in the T1 tumor compared to T2-4 (p 
0.003) and in Stage I compared to Stage II–III (p 0.014), 
Table 2 (continued)
Comparison group Kyn (μM/L) Trp (μM/L) Kyn/Trp ratio
Median ± SD P value Median ± SD P value Median ± SD P value
Pathological complete response to NAC
 Yes 1.813 ± 0.470 0.039* 44.43 ± 11.72 0.292 0.039 ± 0.012 0.367
 No 1.650 ± 0.589 42.00 ± 8.90 0.038 ± 0.016
Relapse
 Yes 1.783 ± 0.627 0.772 45.02 ± 6.46 0.987 0.039 ± 0.014 0.889
 No 1.771 ± 0.524 44.35 ± 11.39 0.038 ± 0.014
The corresponding p values for patients showing or not a pCR and for patients with or without relapse are reported in the table. A significance level of 0.05 is accepted 
(in italics)
Median value of Kyn, Trp and Kyn/Trp ratio according to patient and tumor characteristics, to response to chemotherapy and relapse. The p value was calculated as the 
mean of the Mann–Whitney U test for two variables or the Kruskal–Wallis test for three or more variables
Kyn kynurenine, Trp tryptophan, SD standard deviation, TNBC triple-negative breast cancer, ER estrogen receptor, NAC neoadjuvant chemotherapy
Fig. 1 Scatter dot plots representing the differences in median value between breast cancer patients and healthy controls for Kyn (a), Trp (b) and 
the Kyn/Trp ratio (c). The values were compared by means of the Mann–Whitney U test, and the p value is reported in the figure
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according to the Mann–Whitney U test. The compari-
son by pairs showed a statistically significant difference 
between T1 and T2 and between Stage I and Stage III 
(Additional file 1: Tables S3, S4). Likewise, a negative cor-
relation between the plasmatic Trp level and tumor size 
expressed in mm was observed (Table 3 and Additional 
file 1: Figure S3).
For all the other variables (BC subtype, HER2 expres-
sion, ki67 expression, N stage and lympho-vascular 
invasion), we did not observe any differences in circu-
lating Kyn, Trp and the Kyn/Trp ratio distribution, as 
shown in Table 2 and in Additional file 1: Tables S1–S6.
In addition to the association of plasmatic Kyn, Trp 
and the Kyn/Trp ratio with cancer characteristics, we 
also analyzed their predictive roles in the response 
Table 3 Correlation of Kyn, Trp and Kyn/Trp ratio with the continuous variables age, ER, PgR, Ki67 and size
The correlation was calculated with the Spearman test. The correlation coefficient, 95% CI and p value are reported in the table. The significant correlations are 
reported in italics




95% CI p value Correlation 
coefficient
95% CI p value Correlation 
coefficient
95% CI p value
Age (years) 0.295 0.196 to 0.389 < 0.0001*** 0.028 − 0.078 to 0.133‏ 0.610 0.300 0.200 to 0.393 < 0.0001***
ER (%) 0.010 − 0.129 to 0.148 0.890 0.146 0.008 to 0.279 0.039* − 0.103 − 0.239 to 0.036 0.145
PgR (%) − 0.074 − 0.211 to 0.065 0.297 0.116 − 0.023 to 0.250 0.103 − 0.184 − 0.315 to − 0.046 0.009**
Ki67 (%) − 0.036 − 0.173 to 0.103 0.614 − 0.108 − 0.243 to 0.031 0.128 0.045 − 0.94 to 0.183 0.523
Size (mm) 0.003 − 0.137 to 0.142 0.968 − 0.170 − 0.302 to − 0.031 0.017* 0.119 − 0.021 to 0.254 0.096
Table 4 Kyn, Trp and Kyn/Trp ratio in breast cancer subtypes
The corresponding p values for patients showing or not a pCR and for patients with or without relapse are reported in the table. A significance level of 0.05 is accepted 
(in italics)
Median value of Kyn, Trp and Kyn/Trp ratio in the different breast cancer subtypes according to the response to chemotherapy and relapse tested by the mean of the 
Mann–Whitney U test
Kyn kynurenine, Trp tryptophan, SD standard deviation, PCR pathological complete response, TNBC triple-negative breast cancer
Group (N of pts) Kyn Trp Kyn/Trp ratio
Median ± SD p value Median ± SD p value Median ± SD p value
Luminal A (60 pts) PCR (0) NA NA NA NA NA NA
No pCR (13) 1.710 ± 0.684 NA 36.70 ± 8.26 NA 0.042 ± 0.019 NA
No relapse (53) 1.775 ± 0.582 0.982 48.17 ± 13.02 0.442 0.038 ± 0.014 0.542
Relapse (7) 1.717 ± 0.501 44.67 ± 5.88 0.043 ± 0.009
Luminal B (89 pts) PCR (23) 1.887 ± 0.327 0.001** 44.77 ± 14.17 0.455 0.045 ± 0.011 0.029*
No pCR (42) 1.580 ± 0.463 43.47 ± 8.51 0.036 ± 0.011
No relapse (79) 1.807 ± 0.463 0.194 43.87 ± 10.53 0.447 0.038 ± 0.011 0.119
Relapse (10) 1.653 ± 0.389 46.93 ± 8.42 0.035 ± 0.006
HER2-enriched (14 pts) PCR (7) 1.757 ± 0.790 0.234 39.73 ± 8.12 0.836 0.045 ± 0.018 0.295
No pCR (6) 2.43 ± 0.956 42.42 ± 5.03 0.063 ± 0.028
No relapse (10) 1.828 ± 0.786 0.454 37.80 ± 6.67 0.076 0.047 ± 0.023 1
Relapse (4) 2.398 ± 1.135 46.13 ± 2.94 0.049 ± 0.026
TNBC (39 pts) PCR (13) 1.707 ± 0.476 0.853 44.43 ± 7.98 0.511 0.037 ± 0.008 0.353
No pCR (22) 1.777 ± 0.449 41.97 ± 10.87 0.042 ± 0.013
No relapse (39) 1.648 ± 0.450 0.707 44.78 ± 10.73 0.440 0.037 ± 0.012 0.761
Relapse (7) 1.813 ± 0.437 42.00 ± 4.65 0.042 ± 0.011
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to chemotherapy and cancer relapse (Table  2). We 
observed a statistically significant higher circulating 
Kyn level for patients experiencing a pathological com-
plete response (pCR) after NAC in 126 patients, with a 
value of 1.813 ± 0.470  μM/L vs. 1.650 ± 0.589  μM/L (p 
0.039), but no differences in plasmatic Trp or the Kyn/
Trp ratio were detected. Considering the different breast 
cancer subtypes, we detected a higher plasmatic Kyn 
(1.887 ± 0.327  μM/L vs. 1.580 ± 0.463  μM/L, p 0.001) 
and Kyn/Trp ratio (0.045 ± 0.011 vs. 0.036 ± 0.011, p 
0.029) for Luminal B patients who reached a pCR com-
pared with patients with residual disease, but not sig-
nificant association for the other subtypes (Table  4). 
No significant difference was detected in the four sub-
types between patients experiencing a relapse and those 
not (Table  4). Interestingly, we observed a higher Kyn 
median value, a lower Trp and a higher Kyn/Trp ratio 
in plasma in TNBC with residual disease and in patients 
who relapsed, even if the significance level was not 
reached.
We classified BC patients into different groups accord-
ing to circulating Kyn, Trp and the Kyn/Trp levels using 
the median value in the cancerous patients as the thresh-
old: 1.77 μM/L for Kyn, 44.56 μM/L for Trp and 0.038 for 
the Kyn/Trp ratio. We analyzed DFS and BCSS in these 
groups. Six patients of 202 of the BC cohort were not 
evaluable for survival due to deaths from other causes or 
loss during follow-up. Among the 196 patients included 
in the analysis for survival, we detected 28 progressions 
and 8 deaths. We detected a non statistically significant 
difference in DFS in the groups with low and high plas-
matic Kyn/Trp ratio (Fig. 2c), with a 5-year DFS of 85% 
vs. 73% (p 0.523), respectively. For all the other vari-
ables (low and high circulating kyn and Trp), we did not 
observe any difference in the groups analyzed (Fig. 2 and 
Table 5). 
The analysis of DFS and BCSS in the different BC sub-
types according to circulating Kyn, Trp and the Kyn/Trp 
ratio did not show significant results (Additional file  1: 
Figures S1, S2).
Fig. 2 Kaplan–Meier curves for DFS according to Kyn (a), Trp (b) and the Kyn/Trp ratio (c) and for BCSS according to Kyn (d), Trp (e) and the Kyn/Trp 
ratio (f). The cohort was divided into Kyn low and high groups, Trp low and high groups and Kyn/Trp ratio low and high groups, using the median 
respective value for the cohort affected by breast cancer as a threshold. The statistical significance was calculated by means of a log-rank test for 
each curve, and the corresponding p values are reported in the figure
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Discussion
In this study, we analyzed Kyn and Trp levels and their 
ratios in the plasma of early BC patients and healthy 
CTRLs. To our knowledge, this is the largest study evalu-
ating the plasmatic level of Trp and its metabolite Kyn in 
this setting of patients. The aim of our study was to iden-
tify a difference in circulating Kyn, Trp and the Kyn/Trp 
level in the presence of a BC, according to BC character-
istics and their predictive role on survival, as observed in 
other malignancies.
We met our primary objective to demonstrate the dif-
ference in plasmatic Kyn, Trp and the Kyn/Trp ratio 
between BC patients and healthy CTRLs. Overall, we 
observed lower Kyn and Trp levels in plasma of can-
cerous patients, suggesting rapid Trp catabolism, with 
a possible accumulation of downstream metabolites, 
such as quinolinic and kynurenic acid. The same results 
were shown by Greene and colleagues in a cohort of 77 
BC patients compared to 40 healthy CTRLs [24]. These 
authors also analyzed the plasma level of nicotinamide, 
the final metabolite of Trp catabolism. They observed an 
accumulation of nicotinamide relative to the Trp level in 
plasma of BC patients, which suggests hyperactivation of 
the catabolic pathway [24]. In our study, we also found a 
higher plasmatic Kyn/Trp ratio in healthy CTRLs than in 
BC patients. These results are not consistent with those 
shown in a previously published study by Lyon and col-
leagues, but we note that the sample in this paper com-
prised only 57 subjects vs. 348 in our study [23]. Our 
finding of a lower Kyn/Trp ratio in BC concomitant 
to lower Kyn and Trp levels in plasma suggests a major 
decrease in Kyn vs. Trp in the presence of cancer, prob-
ably due to the hyperactivation of other downstream 
enzymes, such as kynureninase (KYNU) and kynure-
nine hydroxylase. This is consistent with the results of 
D’Amato and colleagues, who observed an upregulation 
not only of TDO but also of KYNU in TNBC cell lines 
[26].
In our study, we observed a higher plasmatic Kyn and 
Kyn/Trp ratio in older women. This result is consistent 
with literature data showing an increase in tryptophan 
metabolism with age, which is known to be associated 
with central nervous system degenerative diseases [27]. 
Analogously, an accumulation of Kyn and other Trp 
products in serum was also observed in aging mice [28].
Hormone receptor (HR) status is also related to Trp 
catabolism, as already shown in the literature, with an 
upregulation of TDO in an NF-κB-dependent manner in 
HR- breast cancer cell lines [26]. This is consistent with 
our finding of a lower circulating Trp level concomitant 
with a higher Kyn/Trp ratio in HR− tumors. Considering 
the known immunosuppressive role of Kyn and the fact 
that HR− BCs are associated with a higher immune infil-
tration, we could not associate the difference in immune 
system activation throughout breast cancer subtypes 
with the plasmatic Kyn/Trp ratio. In fact, plasmatic Kyn 
and Trp levels reflect the systemic Trp catabolism and 
could not be considered a reflection of tumor microen-
vironment, in which the local enzymatic activity deter-
mines the level of metabolites at tumor site.
In stage I tumors compared to Stage II and III tumors 
and in T1 tumors compared to T2-4 tumors, we observed 
a higher plasmatic Trp level, suggesting faster Trp degra-
dation in larger tumors.
In the whole cohort of patients receiving NAC, we 
observed a higher level of circulating Kyn in patients 
experiencing a pCR without any statistically significant 
difference in Trp level or in the Kyn/Trp ratio in plasma, 
while in the Luminal B subtype only, the high Kyn level 
for patients with pCR was concomitant with a signifi-
cant increase in the Kyn/Trp ratio in plasma samples. 
This is in contrast with what was expected, consider-
ing the immunosuppressive role of Kyn and the known 
Table 5 DFS and BCSS according to Kyn, Trp and the Kyn/Trp ratio
Kyn kynurenine, Trp tryptophan, DFS disease-free survival, N number, HR hazard ratio, BCSS breast cancer-specific survival
Outcome Parameter Kyn Trp Kyn/Trp ratio
Low High p value Low High p value Low High p value
DFS N patients 100 96 NA 95 101 NA 98 98 NA
N events 14 14 NA 11 17 NA 13 15 NA
5-year-DFS 80% 79% 0.994 81% 78% 0.602 85% 73% 0.523
HR (95% CI) 1.003 (0.477–2.106) 1.224 (0.572–2.616) 1.273 (0.605–2.679)
BCSS N patients 94 94 NA 90 98 NA 93 95 NA
N events 6 2 NA 5 3 NA 5 3 NA
5-year-BCSS 92% 98% 0.167 94% 96% 0.288 94% 97% 0.586
HR (95% CI) 0.341 (0.069–1.691) 0.469 (0.112–1.964) 0.673 (0.161–2.822)
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association of pCR with TIL infiltration [29, 30]. In addi-
tion, in TNBC with residual disease and with relapse, it is 
interesting to observe a higher Kyn median value, a lower 
Trp and a higher Kyn/Trp ratio. However, the TNBC 
subgroup of our cohort comprised only 39 patients, and 
these results did not reach significance. Nevertheless, this 
study analyzes only Trp and its metabolites in plasma, 
and we cannot exclude a role for Trp catabolism in the 
tumor microenvironment.
Finally, we did not observe any association between 
plasmatic Kyn, Trp or their ratio with survival, in con-
trast to what was observed for other cancer types. In fact, 
previously published studies showed a significant asso-
ciation between a low Kyn/Trp ratio in plasma and longer 
survival in non-small cell lung cancer (NSCLC) treated 
with chemoradiation [14, 15] or immunotherapy [16].
The present study is the largest analyzing plasmatic 
Kyn and Trp levels in BC and in healthy CTRLs. This 
high number of patients allows us to compare the plas-
matic concentrations of these metabolites between 
breast cancer subtypes, disease stage, proliferation 
marker expression, tumor grade, clinical outcome and 
response to chemotherapy. In no other previous studies 
the Trp and Kyn levels were so well described accord-
ing to tumor characteristics, probably due to the small-
est sample size. The plasmatic Trp level could be related 
to fasting, that is a missing information in our cohort. In 
the second instance, we did not measure the circulating 
downstream metabolites after Kyn, which could be use-
ful for better understanding the variations in Trp catab-
olism at any level of the pathway. Moreover, we have to 
take into account that other enzymes are involved in Trp 
catabolism, as well the metabolic pathway at the tumor 
level could be different from systemic catabolism and 
not necessarily reflected in circulating metabolite-level 
modification. Consequently, we cannot consider plas-
matic Kyn and Trp levels as a direct reflection of IDO 
activity in tumor tissue. An analysis of the tumor site in 
addition to the plasmatic measurement of Trp and its 
metabolites could be useful to clarify the correspond-
ence between the circulating and tumor compartments. 
Finally, a longer follow-up could be useful for the survival 
analysis. In our cohort, we observed only 28 events of 
progression and 8 of death out of 196 patients evaluated 
for outcome, which did not allow us to obtain conclusive 
results regarding survival.
Conclusions
In our study, we showed that plasmatic levels of Kyn, Trp 
and the Kyn/Trp ratio could differentiate BC patients from 
healthy CTRLs, but they were not useful for predicting 
the outcome or sensitivity to chemotherapy. According to 
the above observations, breast cancer is associated with 
rapid metabolism that could be systemic or local.
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